This week in techniques



Licensing status

Publication and contact information

Drug delivery

Matrix metalloproteinase 2 (MMP2)-activated, chemotherapeutic nanocarriers for targeted drug delivery

MMP2-activated nanocarriers could provide a drug delivery vehicle for cancer chemotherapies. The nanopreparation consists of a hydrophilic, PEGylated micelle shell that is cleaved by MMP2 and releases paclitaxel bound to a cell-permeable Tat peptide. In human lung carcinoma cells, the nanopreparation had cytotoxicity comparable to that of free paclitaxel and was less toxic than paclitaxel in healthy cardiomyocytes. In mice with non-small cell lung cancer (NSCLC) xenografts, the nanopreparation showed better tumor accumulation and antitumor activity than nontargeted control micelles, conventional paclitaxel-carrying micelles and free paclitaxel. Next steps include testing the nanocarriers in additional tumor models.

SciBX 6(40); doi:10.1038/scibx.2013.1142
Published online Oct. 17, 2013

Patent status undisclosed; available for licensing

Zhu, L. et al. Proc. Natl. Acad. Sci. USA; published online Sept. 23, 2013;
Contact: Vladimir P. Torchilin, Northeastern University, Boston, Mass.